Početna › Multipli mijelom › Florida › Tampa
Kliničke studije za Multipli mijelom u gradu Tampa, FL
15 studija za Multipli mijelom traži sudionike na lokacijama u gradu Tampa i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
U tijeku regrutacijaFaza 1
- Moffitt Cancer Center /ID# 279068, Tampa
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
U tijeku regrutacijaFaza 3
- Research Site, Tampa
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 3
- Moffit Cancer center, Tampa
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
U tijeku regrutacijaFaza 4
- Moffitt Cancer Center, Tampa
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- Moffitt Cancer Center, Tampa
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
- Moffitt Cancer Center, Tampa
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- Moffitt Cancer Center, Tampa
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1/2
- Research Site, Tampa
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
U tijeku regrutacijaFaza 1/2
- Research Site, Tampa
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
U tijeku regrutacijaFaza 3
- Research Site, Tampa
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
U tijeku regrutacijaFaza 1/2
- Moffitt Cancer Center /ID# 272628, Tampa
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
U tijeku regrutacijaFaza 3
- Moffitt at Memorial Healthcare System, Tampa
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1/2
- Moffitt Cancer Center - McKinley Drive, Tampa
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
U tijeku regrutacijaFaza 1/2
- Moffitt Cancer Center, Tampa
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- Moffitt Cancer Center, Tampa
Studije za Multipli mijelom u drugim gradovima
- New York City, NY60 studija
- Boston, MA42 studija
- Atlanta, GA41 studija
- Houston, TX38 studija
- Durham, NC37 studija
- Nashville, TN32 studija
- Denver, CO27 studija
- Rochester, MN24 studija
- St. Louis, MO24 studija
- Columbus, OH24 studija
- Baldwin Park, CA23 studija
- Chicago, IL22 studija
Ostale studije u gradu Tampa
- Nemikrocelularni karcinom pluća51 studija
- Rak dojke43 studija
- Rak (sve vrste)39 studija
- Kolorektalni rak33 studija
- Metastatski karcinom29 studija
- Rak pluća29 studija
- Akutna mijeloična leukemija29 studija
- Rak gušterače26 studija
- Rak jajnika21 studija
- Mijelodisplastični sindromi19 studija
- Melanom19 studija
- Srčano zatajenje18 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.